ImmunityBio’s Sales Surge Amid Strategic Advances

Immunitybio Inc ( (IBRX) ) has released its Q4 earnings. Here is a breakdown of the information Immunitybio Inc presented to its investors.

ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapy platforms to enhance the immune system’s ability to combat cancers and infectious diseases. The company leverages its innovative therapies to create durable immune responses and potential cancer vaccines.

ImmunityBio’s recent earnings report highlights significant sales momentum following the issuance of a permanent J-code for ANKTIV A in January 2025. The company reported a notable increase in unit sales volume for ANKTIV A, with February 2025 sales showing a 67% month-over-month increase from January. Additionally, the company achieved net product revenue of approximately $7.2 million for the fourth quarter of 2024, marking a 21% increase from the previous quarter.

Key financial metrics from the report include a decrease in research and development expenses and an increase in selling, general, and administrative expenses. The net loss attributable to ImmunityBio common stockholders was significantly reduced to $59.2 million for the fourth quarter of 2024, compared to $233.4 million in the same period of the previous year. The company also announced several strategic developments, including FDA authorization for expanded access to recombinant BCG and the acceptance of marketing authorization applications in the EU.

Looking ahead, ImmunityBio’s management remains optimistic about the company’s growth trajectory, emphasizing the potential of ANKTIV A and its RMAT designation to drive future success. The company plans to continue its strategic initiatives and clinical trials to further enhance its position in the immunotherapy sector.